From August 4th to 5th, 2026, the 2026 Frost & Sullivan Summit was held in Shanghai. The event was organized by Frost & Sullivan (hereinafter referred to as "Frost & Sullivan"). It brought together representatives from the industry, capital, and academia, aiming to create the leading platform for corporate investment and financing, and support sustainable and high-quality development.
On August 5, at the "Life Science New Investment Summit Forum - Health Technology Session", Ms. Li Qian, Executive Director of Frost & Sullivan, officially released and interpreted the "2026 Global Synthetic Biology Industry Development White Paper" (hereinafter referred to as "the White Paper"), presenting systematically the current development status and future trends of the global and Chinese synthetic biology industry.
Scan to obtain the complete report.
Li Qian, Executive Director of Frost & Sullivan
This White Paper conducts a systematic study of the current status and future trends of the global and Chinese synthetic biology industry. It comprehensively covers the strategic significance, development history, industrial chain layout, application fields, technological progress, policy environment, capital trends, market landscape, development challenges, and future trends of synthetic biology. The White Paper focuses on analyzing the application progress of synthetic biology technology in the fields of biomedicine, advanced materials, energy, agriculture, consumer goods, and environmental protection. Combining with the practices of representative companies, it explores the key path for synthetic biology technology to move from a single technology to a new stage of integrated platformization, data-driven, and industrialization. It provides industry references and decision-making guidelines for synthetic biology companies, investment institutions, and all industry participants.
01
Overview of Synthetic Biology
01
Strategic Significance of Synthetic Biology
The authoritative definition of Synthetic Biology (also known as Engineering Biology) is: based on biological science, integrating disciplines such as chemistry, physics, and information science, and incorporating engineering principles to design and modify natural or synthetic organisms—both "understanding life through creation" and "applied engineering". The core of synthetic biology is the "convergence" feature—it combines the "discovery ability" of scientific research, the "construction ability" of engineering, and the "invention ability" of disruptive technologies. In 2010, J. Craig Venter's institute chemically synthesized a mycoplasma genome of approximately 1 million bases and implanted it into host cells, obtaining a self-replicating "artificial life" (commonly known as Synthia), proving for the first time that DNA synthesis and reconstruction can reach megabase levels (Gibson et al., Science 2010)—this marked humanity's true ability to "write life". In 2020, AlphaFold2 solved the "protein folding problem" that had plagued the academic community for 50 years, and in 2024, AlphaFold3 could predict the interactions between proteins and other molecules. In the same year, the Nobel Prize in Chemistry was awarded to David Baker (computational protein design) and Demis Hassabis and John Jumper (AlphaFold), marking "AI + protein design" as the core engine of modern science. AI reduced protein screening and optimization from months to hours, and enabled humans to design functional enzymes that do not exist in nature from scratch.
Source: Frost & Sullivan Analysis
The deep integration of BT (biotechnology) + IT (information technology) + AI makes life systems the first to be engineered predictably, reusably, and on a large scale. This is the fundamental reason why it differs from previous biotechnologies and has the attribute of a "platform technology". Because it is a "platform", its impact extends beyond a single industry and penetrates all aspects of the economy like information technology. Currently, synthetic biology and biomanufacturing have been positioned as "key forces driving the Fourth Industrial Revolution" in multiple fields.
Source: Frost & Sullivan Analysis
With the development of synthetic biology technology, since 2022, major economies around the world have intensively introduced top-level designs to gain a competitive edge in synthetic biology, and competition has become increasingly intense. In 2022, the United States signed an Biotechnology Executive Order and launched a national program worth over $2 billion; from 2024 to 2025, the European Union successively introduced the Biotechnology Communication, Life Science Strategy, and the Biotechnology Act; from 2022 to 2025, China's strategic judgments on synthetic biology/biomanufacturing have been upgraded year by year, showing a clear upward trend. In 2026, China will include biomanufacturing in the government work report and incorporate it into the "15th Five-Year Plan Outline" as one of the six future industries, which is a top-level strategic plan for synthetic biology/biomanufacturing. Through "strategic leadership + full-chain coordination + large-scale application", China will accelerate the development of the entire synthetic biology industry.
Source: Frost & Sullivan Analysis
02
Definition and Basic Principles of Synthetic Biology
Research and optimization of synthetic biology generally follow a standardized, data-driven scientific closed loop, namely the Design-Build-Test-Learn cycle (DBTL cycle workflow). The DBTL cycle workflow provides a standardized R&D process for synthetic biology, driven by computer-aided design and high-throughput experimental verification. Through multiple iterations, it continuously optimizes biological systems from design plans to actual performance.
Source: Frost & Sullivan Analysis
03
Global Development History of Synthetic Biology
With the deep integration of artificial intelligence and bi-factories, synthetic biology is transitioning from experience-driven to data-driven. Continuous iteration of the Design-Build-Test-Learn cycle will enhance the quantitative prediction and targeted design capabilities of synthetic biology. With the maturity of underlying technologies such as enzyme-based DNA synthesis, the industrial boundaries of biomanufacturing have been steadily expanded from healthcare to energy chemicals, food agriculture, and environmental governance. The rise of synthetic biology globally provides opportunities for countries to deploy in emerging fields. Since the early 21st century, China has gradually promoted the construction of synthetic biology disciplines and scientific research layout. After more than twenty years of development, significant progress has been made in basic research, technological innovation, and industrial transformation.
Source: Frost & Sullivan Analysis
Source: Frost & Sullivan Analysis
04
Characteristics and Strategic Significance of Synthetic Biology and Biomanufacturing Industries
Synthetic biology and biomanufacturing themselves have the ability to drive industry revolutions and can be applied to multiple industries to help industries break away from traditional industrial paths. At the national level, they have strategic significance; at the same time, top-level designs of national strategies are also leading the industry to develop faster and more efficiently.
The United States locks down the underlying technologies from a national security perspective: relying on the "National Biotechnology and Biomanufacturing Plan" and the NSCEB blueprint, it plans to invest $15 billion over five years, establish a National Biotechnology Coordination Office, classify biological data as territorial assets, and the "Biosecurity Act" excludes purchases from China. Platform companies such as Ginkgo have accumulated the ability of AI + automated bi-factories, and STITCHR has leading capabilities in editing and re-encoding organisms; the weaknesses are slow fermentation capacity return and high manufacturing costs.
China has shifted from being a "biggest fermentation country" to a full-chain approach: accounting for more than 70% of global biorefining capacity, Shenzhen Guangming, Beijing Changping, and Changzhou have formed hundreds of billions of yuan clusters. During the "15th Five-Year Plan", biomanufacturing was listed as new infrastructure; rice hematopoiesis, ten-thousand-ton PHA, and bio-based adipic acid indicate global availability of pilot-scale amplification capabilities. The weaknesses are gene editing tools, high-end instruments, and biological data standards still restricted by Europe and America.
Europe takes a barrier route of "sustainable + strict regulation": in 2025, the "Biobusiness Competitiveness Strategy" and the "European Biotechnology Act" were introduced. The BEA Alliance promises to produce 10 billion euros of bio-based products by 2030; Germany's MaxSynBio leads in synthetic cells, using carbon tariffs/ISCC/PPWR to make "green" an export barrier. Venture capital is only about 1/10 of that in the US, resulting in a fragmented market and slow transformation.
Middle East Capital's Vision under the Belt and Road Initiative Sets a New Position: Saudi Arabia's "National Biotechnology Strategy" aims to become a leader in MENA by 2030. PIF introduces Chinese production capacity, and Jubail builds a 50,000-ton single-cell protein; UAE's Emirates Biotech implements a PLA factory, and Abu Dhabi promotes local CAR-T. The logic is " Sovereign funds buy production capacity + 2030 vision replaces industry + Chinese and Western technologies are introduced", becoming a destination for Chinese synthetic biology enterprises to bypass European and American barriers.
Source: Frost & Sullivan Analysis
02
Analysis of Application Fields and Technological Progress of Synthetic Biology
Synthetic biology is pushing biomedicine into a new stage of precision treatment, platformed R&D, and large-scale manufacturing. In the field of advanced materials, synthetic biology technology, centered on engineered bacteria and biomanufacturing technology, is driving advanced materials to develop in the directions of greenness, high performance, sustainability, and scalability. In the energy sector, engineered enzymes and microorganisms can improve the conversion efficiency of non-grain biomass, reduce costs of traditional biofuels. Additionally, carbon gas fermentation and CO2 bioconversion are breaking the dependence on sugar raw materials, expanding low-carbon fuel production pathways. In the agricultural sector, synthetic biology has dual values. Engineered cell factories can replace traditional farming, planting, and chemical synthesis, enabling low-carbon transformation of agricultural products and plant protection products. Gene editing and metabolic regulation technologies can also overcome the capacity bottlenecks of traditional production models. In the consumer goods sector, cell factories can replace traditional animal and plant extraction or chemical synthesis, achieving green and sustainable production of high-value active components. At the same time, gene modification and metabolic regulation can reduce production costs and overcome the limitations of traditional methods. Applications of synthetic biology in the environmental protection field have covered multiple areas such as environmental monitoring, biodegradation, and biological adsorption, and are evolving from single-functional verification to an integrated "monitoring - treatment - resource recovery" approach.
03
Policy Environment for Synthetic Biology
Affected by differences in technical maturity, industrial chain completeness, and scale capabilities in various regions, different countries and regions are at different stages of development in synthetic biology, and these regional differences are directly reflected in their policy arrangements.
Source: Frost & Sullivan Analysis
04
Development Challenges
Synthetic biology is in a critical period of transition from "lab-driven" to "industry-driven". In the process of achieving full integration from "theoretical feasibility" to "applied feasibility", the industry still faces four structural challenges: technology, business, regulation, and social ethics.
Source: Frost & Sullivan Analysis
05
Future Trends
Synthetic biology is accelerating from technical exploration to industrial implementation through interdisciplinary integration and technological innovation. With the improvement of industry regulations and the expansion of business models, the market size of the synthetic biology industry will continue to grow, entering a critical transition period of industry-driven development.
The integration of artificial intelligence and automation accelerates the R&D closed loop of synthetic biology: Synthetic biology R&D is shifting from single-point optimization based on manual experience to a platformed R&D model centered on data-driven and automated closed loops, continuously improving R&D efficiency, experimental stability, and replicability of results. As the experimental data scale and standardization of artificial intelligence and automation platforms increase, the efficiency, repeatability, and predictability of biological system design will further improve.
Bio-based materials are continuously penetrating, moving towards large-scale replacement of petroleum-based materials: The application scope of bio-based materials is expanding from small-scale demonstration projects to packaging, textile fibers, personal care, and other consumer goods, approaching the economic inflection point of petroleum-based replacement. Companies need to choose different chassis for bio-based material production based on protein structure, quality requirements, production scale, and target. Technology and downstream applications form a cycle, and bio-based materials will encounter an economic inflection point in replacing petroleum-based materials.
Live drugs and gene editing therapies are developing rapidly, expected to enter the market window period: Synthetic biology applications in medicine are transitioning from clinical validation to product launch. In 2022-2023, REBYOTA and oral VOWST products were approved by the FDA for market launch, indicating that live drug therapies represented by the microbiome therapy are entering a standardized and productized stage; in 2023-2024, CASGEVY products for sickle cell disease and transfusion-dependent beta-thalassemia were approved by the FDA, marking the market entry window for gene editing therapies from expectation to reality.
Capital investment is shifting towards faster commercial realization, leading companies strengthening full-chain layout: As financing becomes more rational, capital focus is shifting from general platforms and long-term potential to clear products, industrialization progress, stable revenue, and verifiable profit paths. In the future, companies with integrated R&D, manufacturing, supply chain, and commercialization capabilities are expected to control放大 risks and shorten the market entry period.
